Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era.

Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement Ms. Kolarova reports grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM Isotopen Technologien. Munchen AG, during the conduct of the study; grants from Novartis Pharmaceuticals Corporation, grants from Advanced Accelerator Applications SA, grants from IPSEN PHARMA, grants from ITM. Isotopen Technologien Munchen AG, outside the submitted work. Dr. Valle reports personal fees from Agios, personal fees from AstraZeneca, personal fees from Debiopharm, personal fees from Delcath Systems, personal fees from Genoscience Pharma, personal fees from Imaging Equipment Limited, personal fees from Incyte, personal fees from Ipsen, personal fees from Keocyt, personal fees from Merck, personal fees from Mundipharma EDO, personal fees from Novartis, grants, personal fees and non-financial support from NuCana, personal fees from PCI Biotech, personal fees from Pieris Pharmaceuticals, and personal fees and non-financial support from Pfizer, personal. Dr. de Herder reports grants from Ipsen, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer,and personal fees from AAA, outside the submitted work. Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, other from ABX, personal fees and non-financial support from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees and non-financial support from Siemens Healthineers, non-financial support from GE Healthcare, personal fees from Astellas, and personal fees from yMabs, all outside the submitted work. Dr. Capdevila reports grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Ipsen, personal fees from Exelixis, grants and personal fees from Bayer, grants and personal fees from Eisai, grants and personal fees from Advanced Accelerator Applications, personal fees from Lilly, personal fees from Sanofi, personal fees from Merck Serono, grants from Astrazeneca, outside the submitted work. Dr. Pavel reports other from Novartis, personal fees from AAA, personal fees and other from IPSEN, personal fees from Riemser, other from ITM, during the conduct of the study. Dr. Thawer reports grants from Novartis, other from Novartis, other from Pfizer, other from Abbvie, grants from AstraZeneca, outside the submitted work. Dr. Singh reports other relationships with Pfizer and Ipsen/Novartis, outside the submitted work. Remaining authors declare no conflicts of interest.